We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+7.2%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$642M
AUM Growth
-$79.9M
Cap. Flow
-$91.9M
Cap. Flow %
-14.33%
Top 10 Hldgs %
61.3%
Holding
48
New
10
Increased
10
Reduced
9
Closed
18

Top Buys

Rank Stock Value
1
ECYT
Endocyte, Inc. Common Stock
ECYT
+$27.6M
2
TGTX icon
TG Therapeutics
TGTX
+$22.3M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$21.1M
4
UTHR icon
United Therapeutics
UTHR
+$16.1M
5
EXEL icon
Exelixis
EXEL
+$14.4M

Top Sells

Rank Stock Value
1
PTCT icon
PTC Therapeutics
PTCT
+$35.2M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$34.8M
3
NVCR icon
NovoCure
NVCR
+$22.3M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$13.7M
5
ARNA
Arena Pharmaceuticals Inc
ARNA
+$13.2M

Sector Composition

Rank Sector Weight
1 Healthcare 95.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIRX
26
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2M 0.31%
+28,571
New +$2.17M
ACER
27
DELISTED
Acer Therapeutics Inc
ACER
$1.8M 0.28%
+58,461
New +$1.57M
SRRA
28
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$834K 0.13%
12,271
-44,752
-78% -$4.06M
STRM
29
DELISTED
Streamline Health Solutions
STRM
$153K 0.02%
8,676
– –
CTIC
30
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$46K 0.01%
21,441
-1,515,579
-99% -$3.75M
AMRN
31
CALL
Amarin Corp
AMRN
$299M
– –
-79,810
Closed -$4.93M
AMRN
32
Amarin Corp
AMRN
$299M
– –
-52,841
Closed -$3.27M
CGEN icon
33
Compugen
CGEN
$222M
– –
-759,494
Closed -$2.51M
CLDX icon
34
Celldex Therapeutics
CLDX
$2.99B
– –
-53,632
Closed -$405K
EXEL icon
35
CALL
Exelixis
EXEL
$13.3B
– –
-500,000
Closed -$10.8M
NVCR icon
36
NovoCure
NVCR
$1.73B
– –
-713,998
Closed -$22.3M
RIGL icon
37
Rigel Pharmaceuticals
RIGL
$681M
– –
-340,784
Closed -$9.64M
ACOR
38
CALL
DELISTED
Acorda Therapeutics
ACOR
– –
-1,216
Closed -$4.19M
GBT
39
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-602,200
Closed -$27.2M
GBT
40
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-770,400
Closed -$34.8M
GBT
41
PUT
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-200,000
Closed -$9.04M
ARNA
42
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-302,000
Closed -$13.2M
XLRN
43
CALL
DELISTED
Acceleron Pharma
XLRN
– –
-107,900
Closed -$5.24M
XLRN
44
PUT
DELISTED
Acceleron Pharma
XLRN
– –
-552,300
Closed -$26.8M
ALXN
45
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-110,506
Closed -$13.7M
ACHN
46
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-2,988,716
Closed -$8.46M
NVLN
47
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
– –
-2,500
Closed -$9K
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q3 2018 Portfolio in Review

As of Q3 2018, Great Point Partners held 48 positions worth $642M, down 11% from $722M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Great Point Partners withdrew a net $91.9M in Q3 2018, closing 18 positions and reducing 9 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $34.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 81% a quarter earlier.

Against the trend, Great Point Partners opened a new position in Endocyte, Inc. Common Stock worth $28.5M.

  • Great Point Partners's largest Q3 2018 buy was Endocyte, Inc. Common Stock: 1,606,100 shares worth $28.5M.
  • Great Point Partners added most to United Therapeutics in Q3 2018, an estimated $16.1M increase.
  • Great Point Partners's biggest Q3 2018 reduction was PTC Therapeutics, cutting an estimated $35.2M.
  • Great Point Partners fully exited Global Blood Therapeutics, Inc. in Q3 2018, selling an estimated $34.8M.
  • Great Point Partners's ten largest holdings make up 61% of its $642M portfolio in Q3 2018.
  • Great Point Partners opened 10 new positions and closed 18 in Q3 2018.
  • Great Point Partners's portfolio value fell 11% quarter-over-quarter to $642M.

Based on Great Point Partners's 13F filing for Q3 2018, filed 14 Nov 2018.